📊 RVMDW Key Takeaways
Is Revolution Medicines, Inc. (RVMDW) a Good Investment?
Revolution Medicines is a pre-revenue clinical-stage biotech company with an unsustainable cash burn rate of $913.7M annually against cash reserves of only $383.7M, implying sub-5-month runway. The company reported $1.2B in operating losses and $1.1B net losses with deteriorating EPS (-66.2% YoY), indicating worsening financial trajectory and likely need for dilutive capital raises or major clinical/commercial milestones to survive.
Why Buy Revolution Medicines, Inc. Stock? RVMDW Key Strengths
- Zero debt with Debt/Equity ratio of 0.00x providing financial flexibility
- Strong liquidity position with Current Ratio of 7.14x and $383.7M in cash equivalents
- Favorable stockholders equity of $1.6B relative to $723.2M liabilities showing negative debt burden
RVMDW Stock Risks: Revolution Medicines, Inc. Investment Risks
- Pre-revenue company with $0.00 revenue and no commercial-stage products generating sales
- Catastrophic cash burn of $913.7M annually against $383.7M cash reserves represents critical runway crisis (<5 months at current burn)
- Severely deteriorating profitability with EPS declining 66.2% YoY and operating losses exceeding $1.2B annually
- Dependent on successful clinical trial outcomes or capital markets access to avoid insolvency
Key Metrics to Watch
- Quarterly operating cash flow burn rate and cash runway remaining
- Pipeline clinical trial progress and regulatory milestones
- Equity dilution from any capital raises and their timing relative to cash depletion
Revolution Medicines, Inc. (RVMDW) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 7.14x current ratio provides a solid financial cushion.
RVMDW Profit Margin, ROE & Profitability Analysis
RVMDW vs Healthcare Sector: How Revolution Medicines, Inc. Compares
How Revolution Medicines, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Revolution Medicines, Inc. Stock Overvalued? RVMDW Valuation Analysis 2026
Based on fundamental analysis, Revolution Medicines, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Revolution Medicines, Inc. Balance Sheet: RVMDW Debt, Cash & Liquidity
RVMDW Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Revolution Medicines, Inc.'s revenue has declined by 77% over the 5-year period, indicating business contraction. The most recent EPS of $-3.86 indicates the company is currently unprofitable.
RVMDW Revenue Growth, EPS Growth & YoY Performance
RVMDW Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2024 | N/A | -$68.1M | $-0.94 |
| Q2 2024 | N/A | -$68.1M | $-0.81 |
| Q1 2024 | N/A | -$68.1M | $-0.70 |
| Q3 2023 | N/A | -$57.6M | $-0.87 |
| Q1 2023 | $3.8M | -$57.6M | $-0.72 |
| Q3 2022 | $1.1M | -$37.2M | $-0.72 |
| Q2 2022 | $8.7M | -$37.2M | $-0.60 |
| Q1 2022 | $7.6M | -$37.2M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Revolution Medicines, Inc. Dividends, Buybacks & Capital Allocation
RVMDW SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Revolution Medicines, Inc. (CIK: 0001628171)
📋 Recent SEC Filings
❓ Frequently Asked Questions about RVMDW
What is the AI rating for RVMDW?
Revolution Medicines, Inc. (RVMDW) has an AI rating of STRONG SELL with 88% confidence, based on fundamental analysis of SEC EDGAR filings.
What are RVMDW's key strengths?
Claude: Zero debt with Debt/Equity ratio of 0.00x providing financial flexibility. Strong liquidity position with Current Ratio of 7.14x and $383.7M in cash equivalents.
What are the risks of investing in RVMDW?
Claude: Pre-revenue company with $0.00 revenue and no commercial-stage products generating sales. Catastrophic cash burn of $913.7M annually against $383.7M cash reserves represents critical runway crisis (<5 months at current burn).
What is RVMDW's revenue and growth?
Revolution Medicines, Inc. reported revenue of $0.0.
Does RVMDW pay dividends?
Revolution Medicines, Inc. does not currently pay dividends.
Where can I find RVMDW SEC filings?
Official SEC filings for Revolution Medicines, Inc. (CIK: 0001628171) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is RVMDW's EPS?
Revolution Medicines, Inc. has a diluted EPS of $-5.95.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is RVMDW a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Revolution Medicines, Inc. has a STRONG SELL rating with 88% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is RVMDW stock overvalued or undervalued?
Valuation metrics for RVMDW: ROE of -69.3% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy RVMDW stock in 2026?
Our dual AI analysis gives Revolution Medicines, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is RVMDW's free cash flow?
Revolution Medicines, Inc.'s operating cash flow is $-897.7M, with capital expenditures of $16.0M.
How does RVMDW compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -69.3% (avg: 15%), current ratio 7.14 (avg: 2).